GlassScriptPhysician profile
Lejla Mujic
NPI 1184659351
$1,607.18
in general payments reported to CMS, 2019-2025
18 companies · $230 in 2025
The $230 reported for 2025 was more than what 85% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $13.45 · 2021: $115 · 2022: $68.69 · 2023: $589 · 2024: $332 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $542.09 | 2021-2024 | Veklury |
| Abbvie INC. | $203.10 | 2022-2025 | |
| Medtronic, INC. | $174.91 | 2023 | Accurian |
| Csl Behring | $146.61 | 2023-2025 | Kcentra |
| Portola Pharmaceuticals, LLC | $137.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $129.64 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $50.08 | 2023 | Andexxa |
| Z-Medica, LLC | $46.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.52 | 2019-2022 | |
| Inari Medical, INC. | $23.80 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Molnlycke Health Care US, LLC | $20.74 | 2025 | Mepilex Ag, Mepitel, Mepitel One |
| Bioxcel Therapeutics, INC. | $18.16 | 2023 | Igalmi |
| Melinta Therapeutics, LLC | $15.60 | 2022 | |
| Rare Disease Therapeutics, INC. | $15.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $14.52 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.42 | 2024 | Jardiance |
| Nabriva Therapeutics, Plc | $13.45 | 2020 | |
| Allergan, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lejla Mujic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.